Modality
ASO
MOA
WRNi
Target
PARP
Pathway
STING
MesoEoE
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
Apr 2022
→ Feb 2031
Phase 2Current
NCT05637858
1,725 pts·Meso
2022-04→2031-02·Not yet recruiting
1,725 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-02-144.9y awayPh3 Readout· Meso
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Not yet…
Catalysts
Ph3 Readout
2031-02-14 · 4.9y away
Meso
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05637858 | Phase 2/3 | Meso | Not yet recr... | 1725 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |